NASDAQ NMS - GLOBAL MARKET · IDXX
+0.53% · +$2.97
IDEXX Laboratories Inc

IDEXX Laboratories Inc

Health Care
$560.88

Veridion Score

Loading
Score loading…
Veridion Score History · 90D

Composite trend over time

LOADING HISTORY…
REFRESHES DAILY
AI Analysis
Sovereign

Why is IDXX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About IDEXX Laboratories Inc
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Founded
Listed
1991
Employees
11K
HQ
US

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.

Key statistics

Real vendor fields plus Veridion-computed history. Missing fields stay blank.

Open
$558.44
Day high
$561.74
Day low
$552.23
Previous close
$557.91
52W high
$560.88
0.00% from high
52W low
$556.94
100% of range
Market cap
$44B
P/E
EPS
Dividend yield
Beta
Shares out
78.9M
Float
Volume
516.6K
Avg volume
VWAP
$558.77
Next earnings
Price history computed in-house
1W
+0.71%
1M
+0.71%
3M
+0.71%
1Y
+0.71%
YTD
+0.71%
SMA 50 $558.30 · above
SMA 200 $558.30 · above
52W position 100%
Veridion warehouse edge

Warehouse intelligence for IDXX.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Loading quarterly statements…
SEC Form 4 ledger

IDXX insider activity

IDEXX Laboratories Inc

Score
Coverage building
Pressure
Net selling
Filings
46
Buys / sells
12 / 34
Net value
-$20.7M
Insiders
12
Named filers
FG
FENNELL GEORGE
Insider
Leadership
HL
HOOLEY JOSEPH L
Insider
Leadership
HN
Hunt Nimrata
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$20.7M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-022026-06-01FENNELL GEORGEInsidersell$566.7928410,433$161KSEC Form 4
2026-05-042026-04-30HOOLEY JOSEPH LInsiderbuy$560.8043118$24KSEC Form 4
2026-03-052026-03-03Hunt NimrataInsidersell$634.571,75818,141$1.1MSEC Form 4
2026-03-052026-03-03Underberg Sharon E.Insiderbuy$505.531977,138$100KSEC Form 4
2026-03-022026-02-27MAZELSKY JONATHAN JAYInsiderbuy$505.5319783,803$100KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 41 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Loading PTR filings…
Federal contracts

IDXX contract awards, year to date.

Public federal awards linked to this ticker.

Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IDXX in this window.
Lobbying spend

IDXX lobbying filings, year to date.

Registered lobbying filings matched to IDEXX Laboratories Inc.

Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IDXX in this window.
Latest news · IDXX
Refresh interval: 5 minutes · Source: Market news insights
Loading articles…
Analyst ratings
Sovereign unlock shows live analyst consensus for IDXX.
Options
Sovereign unlock shows live options positioning for IDXX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.